Contrasting Iterum Therapeutics (NASDAQ:ITRM) and Neurocrine Biosciences (NASDAQ:NBIX)

Iterum Therapeutics (NASDAQ:ITRM) and Neurocrine Biosciences (NASDAQ:NBIX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Insider and Institutional Ownership

9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Iterum Therapeutics has a beta of 2.96, indicating that its stock price is 196% more volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.

Profitability

This table compares Iterum Therapeutics and Neurocrine Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Neurocrine Biosciences	21.55%	19.79%	13.82%

Valuation and Earnings

This table compares Iterum Therapeutics and Neurocrine Biosciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390,000.00	4.10	-$24.77 million	($0.75)	-0.04
Neurocrine Biosciences	$2.86 billion	5.77	$478.60 million	$6.49	25.30

Neurocrine Biosciences has higher revenue and earnings than Iterum Therapeutics. Iterum Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for Iterum Therapeutics and Neurocrine Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1	2	0	0	1.67
Neurocrine Biosciences	0	3	18	2	2.96

Neurocrine Biosciences has a consensus target price of $187.52, suggesting a potential upside of 14.22%. Given Neurocrine Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Neurocrine Biosciences is more favorable than Iterum Therapeutics.

Summary

Neurocrine Biosciences beats Iterum Therapeutics on 14 of the 15 factors compared between the two stocks.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.